molmed

Investors

Financial report at 31 march 2014 (in Italian)

Financial report at 31 march 2014 (in Italian) ▾

Investors

MolMed Board of Directors approves the interim financial report at 31 March 2014

MolMed Board of Directors approves the interim financial report at 31 March 2014 ▾

Investors

MolMed reports top line results of NGR-hTNF in the Phase III trial in malignant pleural mesothelioma

MolMed reports top line results of NGR-hTNF in the Phase III trial in malignant pleural mesothelioma ▾

Investors

Resignation of member of the Board of Directors: clarification

Resignation of member of the Board of Directors: clarification ▾

Investors

Resignation of member of the Board of Directors

Resignation of member of the Board of Directors ▾

Investors

MolMed Shareholders’ Meeting approves the Financial Statements 2013

MolMed Shareholders’ Meeting approves the Financial Statements 2013 ▾

Investors

MolMed share capital increase fully subscribed

MolMed share capital increase fully subscribed ▾

Investors

Early closure of the offer on the stock exchange of unexercised pre-emptive rights for the subscription of MolMed ordinary shares

Early closure of the offer on the stock exchange of unexercised pre-emptive rights for the subscription of MolMed ordinary shares ▾

Investors

TK scientific results and regulatory path will be presented today at the 40th annual EBMT meeting

TK scientific results and regulatory path will be presented today at the 40th annual EBMT meeting ▾

Investors

Interim financial report as of 31 March 2014

Interim financial report as of 31 March 2014 ▾

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.